GlaxoSmithKline: Reorganizing Drug Discovery (A) Harvard Case Solution & Analysis

Describes the reorganization of drugs in the GlaxoSmithKline (GSK) after the formation of GSK from the merger of Glaxo Wellcome and SmithKline Beecham. This reorganization has about 2,000 scientists and researchers in the six centers of excellence in drug discovery (CEDD). Each CEDD focused on a small set of therapeutic areas and has the right to address the progression of pharmaceutical drugs in the early stages of development. CEDDs described the proposed structure and its relationship with the rest of the centralized R & D departments of the organization GSK. Address questions about the benefits of diversification in focus against the R & D, the role of decentralized vs. coordinated solutions, and the importance of consistency between structural and infrastructure (for example, performance incentives) aspects of the operating model. Using the empirical context of mergers in the pharmaceutical industry, the event allows students to build a broad idea of ​​the interaction between the legal form and operations. "Hide
by Robert S. Huckman, Eli Peter Strick Source: Harvard Business School 21 pages. Publication Date: May 17, 2005. Prod. #: 605074-PDF-ENG

GlaxoSmithKline: Reorganizing Drug Discovery (A) Case Solution Other Similar Case Solutions like

GlaxoSmithKline: Reorganizing Drug Discovery (A)

Share This